Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Axel Visani"'
Autor:
Irene Bagaloni, Axel Visani, Sara Biagiotti, Annamaria Ruzzo, Mohsen Navari, Maryam Etebari, Lucia Mundo, Massimo Granai, Stefano Lazzi, Alessandro Isidori, Federica Loscocco, Jiejin Li, Lorenzo Leoncini, Giuseppe Visani, Mauro Magnani, Pier Paolo Piccaluga
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Altered cellular energetic metabolism has recently emerged as important feature of neoplastic cells. Indeed, interfering with cancer cell metabolism might represent a suitable therapeutic strategy. In this study, we aimed to assess glucose metabolism
Externí odkaz:
https://doaj.org/article/305e9d07524b48dba08c61891a543639
Autor:
Pier Paolo Piccaluga, Mohsen Navari, Axel Visani, Flavia Rigotti, Claudio Agostinelli, Simona Righi, Erica Diani, Marco Ligozzi, Maria Carelli, Cristina Ponti, Isabella Bon, Donato Zipeto, Santo Landolfo, Davide Gibellini
Publikováno v:
Heliyon, Vol 5, Iss 11, Pp e02643- (2019)
IFI16, member of the IFN-inducible PYHIN-200 gene family, modulates proliferation, survival and differentiation of different cell lineages. In particular, IFI16 expression, which is regulated during the differentiation of B cells, was recently studie
Externí odkaz:
https://doaj.org/article/2446df23ffcd4e33aa2269d21bf57689
Autor:
Maryam Etebari, Mohsen Navari, Claudio Agostinelli, Axel Visani, Cristiano Peron, Javeed Iqbal, Giorgio Inghirami, Pier Paolo Piccaluga
Publikováno v:
Frontiers in Genetics, Vol 10 (2019)
Lennert lymphoma (LL) is a lymphoepithelioid morphological variant of peripheral T-cell lymphoma—not otherwise specified (PTCL/NOS), clinically characterized by better prognosis if compared with other PTCL/NOS. Although well characterized as far as
Externí odkaz:
https://doaj.org/article/28a7c6e3d1934644a53ff14f9d720e3c
Autor:
Flavia Rigotti, Giuseppe Visani, Manal El-Sorady, Shaymaa Khattab, Ashraf Elghandour, Pier Paolo Piccaluga, Mohsen Navari, Axel Visani, Cristiano Peron, Yonis Ahmed, Alessandra Weber
Publikováno v:
Biomedical Journal of Scientific & Technical Research. 15
The FXYD domain containing ion transport regulator 3 (FXYD3) belongs to the FXYD protein family, originally identified by Sweadner and Rael [1] basing on sequence similarity, and accounting in mammal for at least seven members.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f34bd129cba441785b9ce718b33476cc
https://doi.org/10.26717/bjstr.2019.15.002638
https://doi.org/10.26717/bjstr.2019.15.002638
Autor:
Claudio Agostinelli, Marco Ligozzi, Cristina Ponti, Santo Landolfo, Flavia Rigotti, Simona Righi, Axel Visani, Mohsen Navari, Pier Paolo Piccaluga, Maria Carelli, Isabella Bon, Davide Gibellini, Erica Diani, Donato Zipeto
Publikováno v:
Heliyon
Heliyon, Vol 5, Iss 11, Pp e02643-(2019)
Heliyon, Vol 5, Iss 11, Pp e02643-(2019)
IFI16, member of the IFN-inducible PYHIN-200 gene family, modulates proliferation, survival and differentiation of different cell lineages. In particular, IFI16 expression, which is regulated during the differentiation of B cells, was recently studie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b32cdd110d9065765d1576e4f7cfb527
http://hdl.handle.net/11562/1008361
http://hdl.handle.net/11562/1008361
Autor:
Stefania Paolini, Felicetto Ferrara, Francesco Di Raimondo, Axel Visani, Federica Loscocco, Valentina Zammit, Marco B. L. Rocchi, Eleonora Spina, Giuseppe Visani, Alessandro Isidori, Fabio Fuligni, Pier Paolo Piccaluga
Publikováno v:
Leukemia research. 62
Outcome for elderly patients with acute myeloid leukemia (AML) is extremely poor. Intensive induction chemotherapy is often unsuitable. Sixty-six newly diagnosed AML patients (median age: 76 years), ineligible for standard therapy, were consecutively
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ca552f04f9c5040aec5720c174791f1
https://pubmed.ncbi.nlm.nih.gov/28987821
https://pubmed.ncbi.nlm.nih.gov/28987821
Autor:
Axel Visani, Giuseppe Visani, Cristiano Peron, Pier Paolo Piccaluga, Lorenzo Leoncini, Flavia Rigotti
Publikováno v:
Integrative Cancer Science and Therapeutics. 4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c079126a1ea6f48c3e434ee358323ee7
https://doi.org/10.15761/icst.1000245
https://doi.org/10.15761/icst.1000245
Autor:
Alessandro Isidori, F. Di Raimondo, Maria Rita Caraci, Stefania Paolini, Giovanni Sparaventi, Stefano Pileri, Cira Riccardi, Axel Visani, Federica Loscocco, Marco B. L. Rocchi, Maura Rossi, Fabio Fuligni, Pier Paolo Piccaluga, Giuseppe Visani, Maria Antonella Laginestra, Anna Gazzola, Felicetto Ferrara
Low-dose lenalidomide plus cytarabine induce complete remission that can be predicted by genetic profiling in elderly acute myeloid leukemia patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44d69d1ce9413ac822939cbef38f7943
https://hdl.handle.net/11576/2601990
https://hdl.handle.net/11576/2601990
Autor:
Felicetto Ferrara, Maria Rita Caraci, Francesco Di Raimondo, Cira Riccardi, Alessandro Isidori, Axel Visani, Antonella Laginestra, Giovanni Sparaventi, Federica Loscocco, Teresa Ricciardi, Sara Barulli, Barbara Guiducci, Anna Gazzola, Giuseppe Visani, Maura Rossi, Marco B. L. Rocchi, Fabio Fuligni, Pier Paolo Piccaluga
Publikováno v:
Blood. 122:496-496
Outcome for older patients with acute myeloid leukemia (AML) is extremely poor. Intensive induction chemotherapy is often unsuitable. In this phase II study we tested, for the first time, the efficacy of a novel combination therapy with low-dose lena
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::591820c7ad24f7b592e5673be677980d
https://doi.org/10.1182/blood.v122.21.496.496
https://doi.org/10.1182/blood.v122.21.496.496